Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2018

View Archived Issues

Akero Therapeutics closes series A financing to advance development of AKR-001

aTyr Pharma presents positive phase I results for ATYR-1923

Prespecified efficacy endpoint met in phase II study of bemcentinib plus Keytruda in NSCLC

CHMP adopts positive trend vote recommending the approval of the MAA for neratinib

AD and ID

Navitor Pharmaceuticals initiates phase I trial of NV-5138 for treatment-resistant depression

Safety and immunogenicity of ZMapp antibody cocktail for Ebola virus tested in healthy adults

First-in-human data reported for AMV-564 in patients with relapsed/refractory AML

Stemline Therapeutics completes rolling BLA submission to the FDA for Elzonris

Phase II results for CLT-008 in patients receiving AML induction therapy

Increasing the sensitivity of mu-opioid receptors

Enteris reports results from final arm of phase IIa trial of Ovarest

Safety and efficacy of anti-PD-1 antibody SHR-1210 plus apatinib in refractory HCC, GC and EGJC

Phase II trial evaluates antimalarial activity of single-dose DSM-265

FDA approves Zemdri for cUTI, but issues CRL for bloodstream infections

In vivo evaluation of PD-L1-targeted PET imaging agent [64Cu]DK222

Chugai describes OWL-833, an orally active non-peptide GLP-1 receptor agonist

Apellis initiates phase III trial of APL-2 in PNH

Arcus Biosciences, Infinity Pharmaceuticals collaborate on studies of triple combination therapies

Fraunhofer-Gesellschaft describes new bacterial glutaminyl cyclase inhibitors

Ensemble Therapeutics divulges IDO-1 inhibitors

Aclaris initiates phase II trial of ATI-501 for alopecia totalis and alopecia universalis

Pivot plans IND filing to begin clinical trials with PVT-005

FDA advisory committees recommend against approval of Remoxy ER

Servier and Galapagos initiate phase II trial with S-201086 in osteoarthritis

ThromboGenics plans to change name to Oxurion

Summit discontinues development of ezutromid based on results of PhaseOut DMD trial

Phase III trial of rosiptor in interstitial cystitis/bladder pain syndrome misses primary endpoint